FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Investigation

• Publication date

  2008-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/07357900802132550PMID 18798075PMCID PMC2588473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07.

  2016influential reference
• Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

  2007cited by this paper
• Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

  2007cited by this paper
• Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin

  2007cited by this paper
• XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)

  2007cited by this paper
• A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

  2005cited by this paper
• Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years

  2005cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004influential reference
• Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

  1993cited by this paper
• The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.

  1988cited by this paper

• Unveiling anticancer potential of imidazo-pyridine/pyrazine-fused bicyclic heterocycles: insights from in silico and in vitro studies

  2026cites this paper
• Management of gastrointestinal side effects of cancer pharmacotherapy: Part 1: Diarrhoea, constipation, mucositis and anorexia.

  2025cites this paper
• Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma

  2025cites this paper
• Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

  2024cites this paper
• AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer

  2024cites this paper
• Immunotherapy for colorectal cancer

  2024cites this paper
• Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach

  2023cites this paper
• A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea

  2022cites this paper
• Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer

  2022cites this paper
• A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer

  2022cites this paper
• Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment

  2022cites this paper
• Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status

  2021cites this paper
• Cardiac Complications of 5-Fluorouracil (5FU) and Capecitabine Therapy

  2021cites this paper
• Infiltrating T-cell abundance combined with EMT-related gene expression as a prognostic factor of colon cancer

  2021cites this paper
• Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer

  2021cites this paper
• Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancer

  2020cites this paper
• How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain

  2020cites this paper
• Molecular Insights into miRNA-Driven Resistance to 5-Fluorouracil and Oxaliplatin Chemotherapy: miR-23b Modulates the Epithelial–Mesenchymal Transition of Colorectal Cancer Cells

  2019influential citation
• Accuracy of nodal staging is influenced by sidedness in colon cancer.

  2019cites this paper
• Oxaliplatin induced laryngospasm: a case series

  2019cites this paper
• Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea

  2019cites this paper
• Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors

  2019cites this paper
• Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis

  2018cites this paper
• Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer

  2018influential citation
• Chemotherapy treatment: Colorectal cancer patients’ perception

  2018cites this paper
• Systematic evaluation of clinical and experimental evidence for the application of Chinese herbal medicines in the management of colorectal cancer

  2018cites this paper
• Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment

  2017cites this paper
• A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients

  2017cites this paper
• Rôles du couple TrkB/BDNF et de l’autophagie dans la survie de cellules de cancer colorectal

  2016cites this paper
• Whether regional lymph nodes evaluation should be equally required for both right and left colon cancer

  2016cites this paper
• Adjuvant Therapy Trials.

  2016cites this paper
• Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity

  2016cites this paper
• Review Article Immunotherapy for colorectal cancer

  2015cites this paper
• Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases

  2015cites this paper
• Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.

  2015cites this paper
• Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer

  2015cites this paper
• In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH2Ph)]Br.

  2015cites this paper
• A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites

  2015cites this paper
• Oxaliplatin induced pulmonary toxicity—a rare phenomenon

  2015cites this paper
• Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data

  2014cites this paper
• Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

  2014cites this paper
• Increased response of oxaliplatin or irinotecan on in vitro chemosensitivity to 5-fluorouracil in patients with colorectal cancer

  2014cites this paper
• Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

  2014cites this paper
• Time-dependent Estimates of Recurrence and Survival in Colon Cancer: Clinical Decision Support System Tool Development for Adjuvant Therapy and Oncological Outcome Assessment

  2014cites this paper
• Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0

  2014cites this paper
• Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX.

  2014cites this paper
• Gastrointestinal Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX

  2014cites this paper
• Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX

  2013cites this paper
• Colorectal cancer immunotherapy.

  2013cites this paper
• Adoptive T Cell Therapy for Metastatic Colorectal Cancer

  2013cites this paper
• Papel del receptor nuclear de ácidos biliares NR1H4 (“farnesoid X receptor”, FXR) en el control de la expresión de genes implicados en el desarrollo de quimiorresistencia. Características funcionales de sus isoformas

  2013cites this paper
• Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment.

  2013cites this paper
• Colorectal Cancer Surgery in Portal Hypertensive Patients: Does Adjuvant Oxaliplatin Affect Prognosis?

  2013cites this paper
• Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

  2012cites this paper
• Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer.

  2012cites this paper
• Bilateral Simultaneous Frozen Shoulder: A Possible Adverse Event of the Folfox Chemotherapy Regime?

  2012cites this paper
• Therapeutic Kinase Inhibitors

  2012cites this paper
• Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.

  2012cites this paper
• Adjuvant trials of targeted agents: the newest battleground in the war on cancer.

  2012cites this paper
• The effect of diabetes on oxaliplatin-induced peripheral neuropathy.

  2012cites this paper
• Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.

  2012cites this paper
• Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

  2012cites this paper
• Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

  2011cites this paper
• Impact of chemotherapy on health status and symptom burden of colon cancer survivors: a population-based study.

  2011cites this paper
• Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

  2011cites this paper
• A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer.

  2011cites this paper
• Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results–Medicare Data

  2011cites this paper
• The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.

  2011cites this paper
• Recurrence Rates and Prognostic Factors in ypN0 Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision

  2011cites this paper
• Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.

  2011cites this paper
• Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

  2011cites this paper
• Perspectives on the treatment of colorectal carcinoma.

  2010cites this paper
• Molecular bases of liver cancer refractoriness to pharmacological treatment.

  2010cites this paper
• Adjuvant Therapy in Colon Cancer

  2010cites this paper
• Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07

  2009cites this paper
• Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

  2009cites this paper